Skip to content

Released Nov 9, 2017, after the close

10-Q filed Nov 9, 2017, 40 days after period end · 0001390478-17-000074

Q3 2017 · 10-Q
Revenue—
Net Income-$4.46MN/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$2.27no prior Q3 2016 on fileN/M vs Q2 2017
Operating Income-$4,462,000N/M
Operating Cash Flowderived-$2,395,000N/M

What the release said

The release

Same quarter

MetricQ3 2017Q3 2016Q3 2013Q3 2012
Revenue——$2.17M$2.17M
Net Income-$4.46M-$6.93M-$6.93M-$18.03M
EPS Diluted-$2.27—-$0.11-$0.09

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR